Search

Your search keyword '"Yeung, D"' showing total 278 results

Search Constraints

Start Over You searched for: Author "Yeung, D" Remove constraint Author: "Yeung, D" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
278 results on '"Yeung, D"'

Search Results

4. Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia

5. ANZTCT practice statement: sinusoidal obstruction syndrome/veno-occlusive disease diagnosis and management.

6. Tweets versus broadsheets: Sentiment impact on stock markets around the world

9. ECHOCARDIOGRAPHIC PREDICTORS OF TRANSTHYRETIN CARDIAC AMYLOIDOSIS

10. Corporate Governance, Market Conditions and Investors’ Reaction to Information Signals

19. P720: PROACTIVE DASATINIB DOSE REDUCTION IN THE ALLG CML 12 DIRECT STUDY BASED ON TROUGH LEVELS MINIMISE TOXICITY AND PRESERVE EFFICACY

20. PB2176: AN AUSTRALIAN/NEW ZEALAND RANDOMIZED TRIAL OF POST-TRANSPLANT CYCLOPHOSPHAMIDE IN MATCHED RELATED PERIPHERAL BLOOD STEM CELL TRANSPLANTS FOR ACUTE LEUKAEMIA OR MYELODYSPLASIA – ALLG BM12

21. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia

22. Multi-cohort transcriptomic subtyping of B-cell acute lymphoblastic leukemia

25. COVID-19 DIAGNOSIS BY POINT OF CARE LUNG ULTRASOUND: A NOVEL DEEP LEARNING ARTIFICIAL INTELLIGENCE METHOD

26. CARDIAC PHENOTYPING OF SARS-COV-2 IN BC: A PROSPECTIVE ECHO STUDY WITH STRAIN IMAGING

32. An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL

34. Where Goes Momentum?

35. The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia.

36. Sensitivity to sentiment: News vs social media

41. A389 Kynurenic Acid- A clue for different mechanisms of action in Bariatric surgery?

42. De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

43. The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia.

44. Scholarly publishing depends on peer reviewers

45. Scholarly publishing depends on peer reviewers

50. Nilotinib in combination with pegylated interferon Alfa-2b for CP-CML leads to high molecular response rates: Interim results of the pinnacle study.

Catalog

Books, media, physical & digital resources